Modality
Cell Therapy
MOA
Anti-Aβ
Target
C5
Pathway
Hedgehog
PsAMesoPancreatic Ca
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Aug 2028
Phase 1Current
NCT03864739
2,983 pts·PsA
2023-11→2028-08·Not yet recruiting
NCT04712151
1,139 pts·PsA
2018-03→TBD·Active
4,122 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-172.4y awayInterim· PsA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Active
P1
Not yet…
Catalysts
Interim
2028-08-17 · 2.4y away
PsA
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03864739 | Phase 1 | PsA | Not yet recr... | 2983 | HbA1c |
| NCT04712151 | Phase 1 | PsA | Active | 1139 | Biomarker |
Competitors (10)